Statement: In total Less than 10% of patients in the primary trial either had a disease relapse or died.
Primary_evidence: Outcome Measurement:    Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years   Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.   Time frame: Baseline (Month 0) up to 2.75 years Results 1:    Arm/Group Title: Exemestane   Arm/Group Description: Exemestane (Aromasin  ) 25 mg QD for 5 years.   Overall Number of Participants Analyzed: 4898   Measure Type: Number   Unit of Measure: Events (disease relapse or death)  352 Results 2:    Arm/Group Title: Tamoxifen Followed by Exemestane   Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.   Overall Number of Participants Analyzed: 4868   Measure Type: Number   Unit of Measure: Events (disease relapse or death)  388